Diagnostic potential of tumor DNA from ovarian cyst fluid.
Yuxuan WangKarin SundfeldtConstantina MateoiuIe-Ming ShihRobert J KurmanJoy SchaeferNatalie SillimanIsaac KindeSimeon SpringerMichael FooteBjörg KristjansdottirNathan JamesKenneth W KinzlerNickolas PapadopoulosLuis A DiazBert VogelsteinPublished in: eLife (2016)
We determined whether the mutations found in ovarian cancers could be identified in the patients' ovarian cyst fluids. Tumor-specific mutations were detectable in the cyst fluids of 19 of 23 (83%) borderline tumors, 10 of 13 (77%) type I cancers, and 18 of 18 (100%) type II cancers. In contrast, no mutations were found in the cyst fluids of 18 patients with benign tumors or non-neoplastic cysts. Though large, prospective studies are needed to demonstrate the safety and clinical utility of this approach, our results suggest that the genetic evaluation of cyst fluids might be able to inform the management of the large number of women with these lesions.
Keyphrases
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- magnetic resonance
- prognostic factors
- gene expression
- dna methylation
- genome wide
- single molecule
- circulating tumor
- risk assessment
- patient reported outcomes
- copy number
- climate change
- patient reported
- contrast enhanced
- circulating tumor cells